Pt-based drugs were extensively used to treat a large number of tumors in the clinic.^[@ref1]−[@ref10]^ However, cisplatin (*cis*-\[PtCl~2~(NH~3~)~2~\]) and its derivatives were limited by drug resistance and some severe side effects,^[@ref11][@ref14]^ and consequently, the Ru, Ti, Au, Co, Ir, Os, Rh, Fe, Cu, etc., complexes have been designed and attracted attention.^[@ref16]−[@ref38]^ In addition, cobalt has emerged as a key of vitamin B12 (cobalamin) metabolism and its metal complexes have been reported as DNA cleavage agents, antiviral, antifungal, antitumor antiproliferative, antioxidant, and have shown antimicrobial activity, such as oxoisoaporphine,^[@ref15]^ shydroxamic acids prodrugs,^[@ref16],[@ref17]^ 2-benzimidazole derivatives,^[@ref18]^ acetylenehexacarbonyldicobalt,^[@ref19]^ 2-acetylpyridine and malonic acid dihydrazide,^[@ref20]^ antiulcer drug famotidine,^[@ref21]^ sparfloxacin,^[@ref23]^ valine-derived Schiff bases,^[@ref24]^*N*-benzoyl-*N*′-dialkylthiourea derivatives,^[@ref25]^ nonsteroidal anti-inflammatory drugs,^[@ref28]^ nonsteroidal anti-inflammatory drug tolfenamic acid,^[@ref30]^ 2-acetoxy-(2-propynyl)benzoate\]hexacarbonyldicobalt,^[@ref31]^ a fluorescent coumarin,^[@ref32]^ and tetradentate phenolate-based ligand^[@ref35]^ cobalt(II/III) complexes.

Recently, many novel hydroxyquinoline metal compounds, such as Zn, Cu, Ni, Ir, Os, Rh, Au, Co, Fe, Sn, Ru, Pt, Pd, and Ln metal complexes,^[@ref39]−[@ref60]^ have proved to be promising anticancer drugs *in vitro* and *in vivo*. Among them, a small amount of copper(II) complexes of hydroxyquinolines were designed and preliminarily identified as anticancer drugs.^[@ref50]−[@ref60]^ However, to date, Co(II) complexes bearing 5,7-dihalo-2-methyl-8-quinolinol and *o*-phenanthroline derivative mixed ligands have not been reported.

To gain the mixed chelating cobalt(II) complexes with high anticancer activity *in vitro* and *in vivo*, we first designed 18 novel Co(II) complexes **Co1**--**Co18** with 2,2′-bipyridine (py), 1,10-phenanthroline (Phen), 5,7-dichloro-2-methyl-8-quinolinol (H-QL1), dipyridoquinoxaline (DPQ), 5,7-dibromo-2-methyl-8-quinolinol (H-QL2), dipyridophenazine (DPPZ), 5,6-dimethyl-10-phenanthroline (MDP), 4,4′-dimethoxy-2,2′-bipyridyl (ODP), 4,7-diphenyl-10-phenanthroline (PPT), 4,7-dichloro-1,10-phenanthroline (ClPT), 5-chloro-7-iodo-8-hydroxy-quinoline (H-QL3), 5,5-dimethyl-2,2-dipyridine (dpy), 5,7-diiodo-8-hydroxyquinoline (H-QL4), 4,4′-dimethyl-2′-bipyridine (mpy), and 5,7-dibromo-8-quinolinol (H-QL5). Additionally, the biological properties of **Co1**--**Co18** have been evaluated.

First, the mononuclear complexes **Co1**--**Co18** were prepared by CH~3~CN--CH~3~OH (3.5 mL/1.5 mL) reflux of H-QL1 (or H-QL2, H-QL3, H-QL4, H-QL5) and py, Phen, DPQ, DPPZ, MDP, ODP, PPT, ClPT, dpy, and mpy with cobalt(II) acetate (2:1:1) at 80 °C for 24 h, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). These 18 new Co(II) complexes were structurally fully characterized ([Figures [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} and [S1--S45](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)).

![General Synthetic Pathway for **Co1**--**Co18**](ml9b00356_0007){#sch1}

![Crystal structures of **Co1** and **Co7**.](ml9b00356_0001){#fig1}

The Co(II) atoms in **Co1**--**Co18** were six-coordinated and surrounded by two deprotonated QL ligands (N^∧^O-ligand) and one second ligand molecule (N^∧^N-ligand) showing a distorted octahedral geometry ([Figures [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} and [S1--S16](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)). In addition, a diagram of **Co1**--**Co18** is shown in [Figures [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} and [S1--S16](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf), and selected bond distances (Å) and angles (deg) are listed in [Tables S1--S54](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf), and the bond lengths (Å) of **Co1**--**Co18** remained normal.

MTT assay was carried out to gauge the *in vitro* anticancer activity of **Co1**--**C o18**, H-QL1, H-QL2, py, Phen, DPQ, DPPZ, MDP, ODP, PPT, ClPT, H-QL3, dpy, H-QL4, CoCl~2~·6H~2~O, mpy, and H-QL5 using BEL-7404 (hepatocellular), Hep-G2 (hepatocellular), HeLa (cervical), MCF-7 (breast) cancer cells, and normal HL-7702 (hepatocyte) cells. As a general observation ([Table S55](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)), **Co7** was more active (IC~50~ values = 0.80 nM) than the **Co1**--**Co6**, **Co8**--**Co18**, cisplatin, H-QL1, H-QL2, py, Phen, DPQ, DPPZ, MDP, ODP, PPT, ClPT, H-QL3, dpy, H-QL4, CoCl~2~·6H~2~O, mpy, and H-QL5 in all tested cells, and the cytotoxicity of **Co1**--**Co18** against HeLa cells followed the order **Co7** \> **Co5** \> **Co8** \> **Co11** \> **Co3** \> **Co10**\> **Co9** \> **Co13** \> **Co1** \> **Co6** \> **Co4**\> **Co2** \> **Co12** \> **Co18** \> cisplatin \> **Co15** \> **Co17** \> **Co14** \> **Co16**. The higher *in vitro* anticancer activity for **Co7** may be due to the H-QL1 and DPPZ ligands. Such observed, different antitumor effects may be due to the electronic effect of the methyl group and the halogenated and more extended planar ligand of H-QL1 and DPPZ. Interestingly, **Co1**--**Co18** showed low toxicity (IC~50~ \> 60.0 μM) to normal HL-7702 (hepatocyte) cells. Compared with previously reported 8-hydroxyquinoline metal complexes (IC~50~ ≥ 1.00 nM),^[@ref39]−[@ref60]^**Co7** exhibited higher cytotoxicity against HeLa cells (IC~50~ = 0.80 ± 0.21 nM).

Thus, ICP-MS assay showed that the Co(II) concentrations of **Co7** ((22.96 ± 0.15 nmol of Co)/10^6^ cells) and **Co1** ((18.06 ± 0.05 nmol of Co)/10^6^ cells) were significantly above those of control groups and cisplatin ((4.11 ± 0.59 nmol of Pt)/10^6^ cells),^[@ref15]^ with **Co7** (0.80 nM) showing the highest cell accumulation of Co ((22.96 ± 0.15 nmol of Co)/10^6^ cells) and a high extent in HeLa nuclear fraction ([Table S56](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)). Thus, **Co7** (0.80 nM) showed higher toxicity on the HeLa (cervical) cancer cells possibly due to its better cellular uptake.

Thus, the induction of the level of c-myc, hTERT, and thus, telomerase in HeLa cells by **Co1** (4.53 μM) and **Co7** (0.80 nM) was investigated using a TRAP-silver staining assay and Western blot. As shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, **Co7** (0.80 nM) showed a more inhibitory effect on c-myc, hTERT, and telomerase activity than that of **Co1** (4.53 μM), suggesting that **Co1** (4.53 μM) and **Co7** (0.80 nM) inhibited c-myc and hTERT, and thus, telomerase levels were related to a variety of malignant cancers.^[@ref61]−[@ref65]^ Importantly, inhibition of telomerase in **Co7** (0.80 nM)-treated cells was 44.10%, while that caused by **Co1** (4.53 μM) only reached 7.13%.

![Level of telomerase (A) and related factors (B,C) in HeLa cells induced by **Co1** (4.53 μM) and **Co7** (0.80 nM) at 24 h.](ml9b00356_0002){#fig2}

Furthermore, a G2/M population of 22.89% was observed in **Co7** (0.80 nM)-treated cells, while the other corresponding G2/M populations of 20.27% and 12.35% were observed in the **Co1** (4.53 μM) treated and control cells ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), suggesting that **Co1** (4.53 μM) and **Co7** (0.80 nM) caused G2/M cycle arrest. In addition, **Co7** (0.80 nM) and **Co1** (4.53 μM) could inhibit the expression of cyclin B1 and CDK1 in HeLa (cervical) cells ([Figure S46](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)), mainly due to the G2/M phase arrest ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) that they cause and their ability to inhibit telomerase.^[@ref66]−[@ref68]^ Further, immunofluorescence ([Figure S47](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)) and Western blot assays ([Figure S46](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)) were carried out. Clearly, **Co7** (0.80 nM) and **Co1** (4.53 μM) could up-regulate the H2A.X and cleaved-PARP levels, indicating that **Co7** (0.80 nM) and **Co1** (4.53 μM) remarkably induced DNA damage ([Figures S46 and S47](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)) and caused G2/M phase arrest following the order of **Co7** \> **Co1**.

![**Co7** (0.80 nM) and **Co1** (4.53 μM) caused G2/M phase arrest for 24 h.](ml9b00356_0003){#fig3}

In addition, **Co7** (0.80 nM) mainly accumulated in a nuclear fraction ([Table S56](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)) but also was distributed in the mitochondria. Thus, **Co7** (0.80 nM) and **Co1** (4.53 μM) caused obviously up-regulated reactive oxygen species (ROS, [Figure S48](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)), intracellular \[Ca^2+^\] ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), and caspase-3/9 levels ([Figure S49 and S50](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)), and down-regulated mitochondrial membrane potential (ΔΨm) ([Figure S51](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)) in HeLa cells, illustrating that the ΔΨm, ROS generation, intracellular \[Ca^2+^\], and caspase-3/9 played a key role in cancer mitochondrial function damage and apoptosis.^[@ref15],[@ref69]−[@ref72]^

![Effects of **Co7** (0.80 nM) and **Co1** (4.53 μM) on the \[Ca^2+^\] level in HeLa cells at 24 h.](ml9b00356_0004){#fig4}

Therefore, to clarify the antimigration effects of **Co7** (0.80 nM) and **Co1** (4.53 μM) in HeLa cells ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}a--d), the trans-well migration assay was carried out. It was found that **Co7** (0.80 nM) could significantly induce cell migration at 0.80 nM than that of **Co1** (4.53 μM).

![Antimigration (a--d) and apoptosis (e--g) effect of **Co7** (0.80 nM) and **Co1** (4.53 μM) on HeLa cells for 24 h.](ml9b00356_0005){#fig5}

For this, to further investigate the ability of **Co7** (0.80 nM) and **Co1** (4.53 μM) to induce HeLa cell apoptotic by flow cytometry (FCM). As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}e--g, the percentages of apoptotic cells treated with **Co7** (0.80 nM) and **Co1** (4.53 μM) were 95.68% and 34.42%, respectively, suggesting that Co complexes could cause cell death at higher rates than other 8-quinolinate metal complexes.^[@ref39]−[@ref60]^

Furthermore, treatment of HeLa xenografts by **Co7** (2.0 mg/kg/q2d) was related to significant reduction (TIR = 43.7%, *p* \< 0.05) in tumor growth ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} and [Tables S57--S59](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)), which represents approximately 1.3-fold reduction compared with cisplatin-treated groups (IR = 35.2 ± 5.8%, *p* \< 0.05).^[@ref51],[@ref55],[@ref56],[@ref72]−[@ref74]^ In addition, **Co7** (2.0 mg/kg/q2d)-treated mice displayed no obvious signs of toxicity ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} and [Tables S57--S59](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf)) as indicated by a relatively stable mouse body weight (*m*~end~= 20.5 ± 1.3 g) compared to solvent control (*m*~end~= 20.7 ± 1.4 g).

![Tumor volume (A, mm^3^ ± SD) and images (B) of the HeLa tumors of **Co7** (*n* = 6) for 21.0 days.](ml9b00356_0006){#fig6}

In conclusion, we have shown **Co1**--**Co18** complexes containing mixed 5,7-dihalo-8-quinolinol (H-QL1--H-QL5) and 2,2′-bipyridine derivative-based ligands as potential Co(II) complexes with superior cytotoxicity compared with previously reported Co compounds. MTT studies have demonstrated that **Co7** was ca. 300.6 times more cytotoxic than cisplatin (15.03 ± 1.05 μM), with IC~50~ values of 0.80 ± 0.21 nM while maintaining a high extent in HeLa nuclear fraction and targeting telomerase; thus, it was considerably less cytotoxic to normal HL-7702 (hepatocyte) cells. In addition, the antitumor activity of **Co7** has been evaluated *in vivo* against HeLa xenograft growth (TIR = 43.7%, *p* \< 0.05). It also inhibited telomerase activity, caused G2/M phase arrest, and induced mitochondrial dysfunction at a 104.6-fold lower concentration than **Co1** (4.53 μM) in related assays. Thus, the superior cytotoxicity (IC~50~ = 0.80 ± 0.21 nM) and selectivity index of **Co7** in comparison to cisplatin could make it a novel antitumor cobalt(II)-based drug.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.9b00356](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.9b00356).Detailed experiments of **Co1**--**Co18** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00356/suppl_file/ml9b00356_si_002.pdf))
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